TORONTO, ON, JANUARY 13, 2020 –– INTELLiSTEM Technologies, an international biotechnology company revolutionizing cell therapy, announces today the launch of IntelliPeptidomeTM, a novel Drug Discovery Platform for rapid and systematic identification of MHC/HLA bound peptide candidates for various clinical applications. [Read more…]
Aegle Therapeutics Raises $4M to Fund First Trial in the U.S. Using Exosomes from Allogeneic MSCs
Aegle Therapeutics raises $4 million to fund a groundbreaking stem cell exosome clinical trial to treat the orphan disease, Dystrophic Epidermolysis Bullosa.
BOSTON and MIAMI, Jan. 7, 2020 — Aegle Therapeutics Corp., a first in class biotechnology company isolating extracellular vesicles, including exosomes (“EVs”), secreted by mesenchymal stem cells as therapy, announced the closing of a $4M financing. Aegle’s platform technology is initially being developed to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric skin blistering disorder. [Read more…]
BMS Pays Evotec $6M as Companies Expand iPSC Collaboration
Adding Cell Types Supports Drug Discovery of Disease-Modifying Therapies for Neurodegenerative Diseases and Triggues U.S. $6 M Payment to Evotec
Hamburg, Germany, January 7, 2020 – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company (NYSE:BMY) following the decision to expand the collaboration to include additional cell lines.
Evotec and Celgene, which is now a Bristol-Myers Squibb company, initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of patients’ symptoms and there is a huge unmet medical need for therapies that slow down or reverse disease progression in the field of neurodegenerative diseases.
This collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging several of Evotec’s unique technology platforms in conjunction with the human iPSC based platform, which is one of the largest and most sophisticated platforms in the industry. The iPSC partnership between Bristol-Myers Squibb and Evotec has already been expanded with additional cell lines several times. [Read more…]
StemBioSys Acquires a Majority Stake in Cartox
SAN ANTONIO, TX and ANN ARBOR, MI, January 8, 2020 – StemBioSys, Inc. (StemBioSys) and CarTox, Inc. (Cartox) are pleased to announce that StemBioSys has acquired a majority stake in Cartox. StemBioSys will acquire all remaining equity of Cartox subject to the achievement of certain milestones. [Read more…]
GIOSTAR Chicago Launches GIOTalk – a New Healthcare Podcast
Program features discussions with key players in the healthcare industry
CHICAGO, Illinois, December 4, 2019 — GIOSTAR Chicago – a leader in regenerative technologies – is proud to introduce GIOTalk, a podcast focusing on stem cells and broader issues impacting the field of healthcare.
Hosted by renowned plastic surgeon Dr. Michael Gellis, GIOTalk features interviews with medical practitioners and researchers, along with patients looking to share their experiences with stem cell therapy. Through these discussions, GIOSTAR Chicago seeks to provide listeners with diverse perspectives on this dynamic industry. [Read more…]
